00FDA-VAPING1-superJumbo

Dangers of ‘Nicotine free’ Synthetic Products: A Look into Nicotine Analogues

19 October 2026

The use of synthetic nicotine known as nicotine analogues, such as 6-methyl nicotine (6MN) and nicotinamide, are falling under the radar due to a lack of regulation and transparency while causing serious health concerns.  

Nicotine analogues, defined by the Truth Initiative as “…chemical compounds that are structurally similar, but not identical, to nicotine and have activity at nicotinic receptors in the brain”, are being used in e-cigarettes, vapes, pouches and other nicotine products, marketed as less harmful nicotine substitutes. Because nicotine analogues are tobacco free, they are able to bypass regulations without needing to be transparent about any health effects or harms. While we still do not have a clear understanding of their impact on people’s health, recent academic research highlights the dangers of the use and promotion of these products,  

“This is misleading for teens and young adults, as they may be using products marketed as “safer” and “nicotine-free” without knowledge of their ingredients.” (Graham & Corteselli, 2026) 

The use of analogues in nicotine products means they are often aimed at young people, exposing them to unknown health harms. In fact, the Truth Institute states that “6-methyl nicotine is as addictive or possibly more addictive than nicotine.” Additionally, according to the Lancet Respiratory Medicine, early data suggests that these products are in fact harmful and toxic for people’s bodies yet frequently marketed as safer than nicotine. Furthermore, the use of 6-methyl nicotine used in vapes often exceeds the EU limit of 20 mg/mL for nicotine, once again highlighting the lack of regulation and its serious consequences on young people’s health. 

While research on the impact of nicotine analogues has started, more must be done to understand and appropriately classify these chemicals. More information and awareness of ‘nicotine free’ products is also needed to prevent false information and harmful marketing towards young people and the public. According to the Lancet Respiratory Medicine, the time to act is now,  

“Regulatory inertia in the face of chemical innovation has led to missed opportunities before, but with 6-methyl nicotine and its analogues, there is still time to act.” 

Ultimately, only through accurate classification, increased regulation, awareness, and labelling can we prevent further harm.  

 

Sources: 

Nicotine analogues in e-cigarettes: overlooked health risks and inadequate regulatory oversight | Toxicological Sciences | Oxford Academic 

What are nicotine analogs? How a tiny chemical distinction creates a regulatory gap 

The rise of nicotine analogues in vaping products – The Lancet Respiratory Medicine 

 Image: The Synthetic Nicotine Loophole Fueling a Return to Teenage Vaping – The New York Times